Indeed, preclinical data showed that the combination of anti-PD-1 or anti-PD-L1 with BRAF inhibition enhanced antitumor responses in a BRAF/PTEN inducible melanoma model (46), thus warranting clinical studies. Here, CD274 is linked to melanoma.